Drug intelligence / Profile preview

Bifidobacterium breve BL3406

Development stage: Unknown
Lead developer: Probiotical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium breve BL3406 is a specific probiotic bacterial strain developed as a live biotherapeutic product. It is primarily investigated for its immunomodulatory properties, particularly in the context of autoimmune diseases like rheumatoid arthritis. In clinical settings, BL3406 is often administered as part of a multi-strain probiotic consortium (including Lactobacillus casei BLn2401 and Lactobacillus salivarius BL2201) to supplement conventional disease-modifying antirheumatic drugs (cDMARDs). The strain is thought to exert its therapeutic effect by modulating the gut-joint axis, enhancing gut barrier integrity, and shifting the immune response toward a more regulatory, anti-inflammatory state. Clinical trials have demonstrated that adjunctive treatment with this strain can lead to significant reductions in disease activity (DAS28), inflammatory markers such as C-reactive protein, and patient-reported pain and disability.

Other names: Bifidobacterium breve

Beyond the preview

Go deeper on Bifidobacterium breve BL3406.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium breve BL3406.

Explore the full profile